Provided by Tiger Trade Technology Pte. Ltd.

Merck

105.66
+5.265.24%
Pre-market: 105.49-0.1700-0.16%04:10 EST
Volume:22.23M
Turnover:2.32B
Market Cap:262.25B
PE:13.98
High:105.84
Open:100.73
Low:100.71
Close:100.40
52wk High:105.84
52wk Low:73.31
Shares:2.48B
Float Shares:2.48B
Volume Ratio:1.04
T/O Rate:0.90%
Dividend:3.24
Dividend Rate:3.07%
EPS(TTM):7.56
EPS(LYR):6.76
ROE:39.49%
ROA:13.76%
PB:5.06
PE(LYR):15.63

Loading ...

Merck Canada and the Pan-Canadian Pharmaceutical Alliance (Pcpa) Successfully Complete Negotiations for Winrevair® (Sotatercept)

THOMSON REUTERS
·
Nov 20

Merck Group to Leverage Valo Health's AI Technology for Drug Development

Deep News
·
Nov 20

Merck KGaA to draw on Valo's drug discovery AI in potential $3 billion deal

Reuters
·
Nov 20

Merck Nearing Deal For Flu Treatment Start-Up Cidara - FT

Reuters
·
Nov 20

FDA Approves Label Update For ProQuad MMRV Vaccine

Reuters
·
Nov 20

Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial

Reuters
·
Nov 19

Merck reports ‘positive’ results from Phase 3 trial of doravirine/islatravir

TIPRANKS
·
Nov 19

Merck's oral HIV treatment meets main goal in late-stage study

Reuters
·
Nov 19

Merck Gets European Approval for Subcutaneous Keytruda

Dow Jones
·
Nov 19

Merck Reports Positive Phase 3 Results for Two-Drug HIV Regimen Doravirine/Islatravir

Reuters
·
Nov 19

Merck Announces Positive Topline Results From the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (Dor/Isl) in Treatment-NaÏVe Adults With Hiv-1 Infection

THOMSON REUTERS
·
Nov 19

Merck & Co Inc - Dor/Isl Demonstrates Non-Inferiority to Bic/FTC/Taf in Phase 3 Trial

THOMSON REUTERS
·
Nov 19

Merck & Co Inc - FDA Sets Target Action Date of April 28, 2026, for Dor/Isl

THOMSON REUTERS
·
Nov 19

Merck: EC approves subcutaneous administration of Keytruda

TIPRANKS
·
Nov 19

Merck Wins EU Approval for First Subcutaneous KEYTRUDA Administration

Reuters
·
Nov 19

European Commission Approves Subcutaneous Administration of Keytruda® (Pembrolizumab) for All Adult Indications Approved in the European Union

THOMSON REUTERS
·
Nov 19

Berenberg Raises Price Target on Merck to $95 From $90, Keeps Hold Rating

MT Newswires Live
·
Nov 19

Merck & Company (MRK) Gets a Hold from Deutsche Bank

TIPRANKS
·
Nov 19

Post-Bell | U.S. Stocks Dip; Tesla and Palantir Fall 2%; Nvidia and Microsoft Drop 3%; PDD Holdings Sinks 7%

Tiger Newspress
·
Nov 19

Merck & Co. Inc. Stock Rallies 3.8%, Outperforms Peers

Dow Jones
·
Nov 19